New Challenge to Thai Drug Licensing (Thailand)
This article was originally published in PharmAsia News
Emcure Pharmaceuticals is being threatened with legal action by the Sanofi-Aventis, patent holder of the cardiac drug Plavix. Emcure secured an order from the Thai government to produce clopidogrel, the generic version of Plavix. In a notice to Bioscience Co. Ltd, the agent of Emcure in Thailand, Sanofi-Aventis said that any unauthorized importation, manufacture, and sale of the generic clopidogrel will infringe Sanofi's patent rights of clopidogrel under Thai law. Sanofi says that in the event of infringement of its patent, the company "will be entitled to sue the company in a civil action for compensation. Emcure says it has received assurances of support from the Thai government. (Click here for more
You may also be interested in...
Chobani introduces Chobani Probiotic, its first functional probiotics beverage to support digestive and immune health; Danone North America extends its Danimals children’s yogurt line with products to support immune system; and Plexus Worldwide and Sofar Americas roll out children’s probiotics.
Report quantifies social media posts describing adverse events involving the Essure contraceptive device, which was pulled from the market amid safety concerns.
Deal Snapshot: The China/US CAR-T firm will be bought out by its management team and institutional investors in a deal structured as a merger into a new company.